Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients

P Savoia, E Zavattaro, O Cremona

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors. METHODS & RESULTS: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included. CONCLUSION: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Original languageEnglish
Pages (from-to)687-697
Number of pages11
JournalCurrent Medicinal Chemistry
Volume25
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Transplants
Chemoprevention
Skin
Carcinoma
Immunosuppressive Agents
Basal Cell Carcinoma
Electronic mail
Squamous Cell Carcinoma
Neoplasms
Appointments and Schedules
Carcinogenesis
Cells
Morbidity
Mortality
Transplant Recipients
Incidence
Infection
Pharmaceutical Preparations
Population
Therapeutics

Cite this

Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients. / Savoia, P; Zavattaro, E; Cremona, O.

In: Current Medicinal Chemistry, Vol. 25, No. 6, 2018, p. 687-697.

Research output: Contribution to journalArticle

@article{967c06a434674b4ca8aa1bb7196df5e5,
title = "Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients",
abstract = "BACKGROUND: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors. METHODS & RESULTS: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included. CONCLUSION: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients. Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
author = "P Savoia and E Zavattaro and O Cremona",
year = "2018",
doi = "10.2174/0929867324666171003123056",
language = "English",
volume = "25",
pages = "687--697",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients

AU - Savoia, P

AU - Zavattaro, E

AU - Cremona, O

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors. METHODS & RESULTS: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included. CONCLUSION: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

AB - BACKGROUND: Long-term immunosuppressive therapy, as provided to solid organ transplant recipients, inevitably results in a significant inhibition of immune defenses; this leads to frequent skin infections and malignancies, which represent an important cause of morbidity and mortality for transplanted patients. The incidence and risk of skin carcinomas are elevated in solid organ transplant recipients in comparison with the general population, with a 10-fold increased risk for basal cell carcinoma and a 50-100-fold for squamous cell carcinoma. The schedule of immunosuppressive drugs influences the type and timing of skin malignancies, but a crucial role is also played by endogenous and exogenous risk factors. METHODS & RESULTS: Here, we will review the state-of-the-art in chemoprevention of epidermal carcinomas in order to provide useful information for clinicians involved in the management of transplant recipients. One-hundred and forteen paper, published on peerreviewed journals, has been included. CONCLUSION: Chemoprevention would be key in controlling skin carcinogenesis in high-risk patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

U2 - 10.2174/0929867324666171003123056

DO - 10.2174/0929867324666171003123056

M3 - Article

VL - 25

SP - 687

EP - 697

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 6

ER -